CN102786433B - 一种延胡索酰胺类化合物提取物及其制备方法和应用 - Google Patents
一种延胡索酰胺类化合物提取物及其制备方法和应用 Download PDFInfo
- Publication number
- CN102786433B CN102786433B CN201210068581.3A CN201210068581A CN102786433B CN 102786433 B CN102786433 B CN 102786433B CN 201210068581 A CN201210068581 A CN 201210068581A CN 102786433 B CN102786433 B CN 102786433B
- Authority
- CN
- China
- Prior art keywords
- fumaryl
- aminated compounds
- extract
- acetate content
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 47
- 239000000284 extract Substances 0.000 title claims abstract description 41
- QIQCZROILFZKAT-UHFFFAOYSA-N tetracarbon dioxide Chemical group O=C=C=C=C=O QIQCZROILFZKAT-UHFFFAOYSA-N 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 8
- 206010002383 Angina Pectoris Diseases 0.000 claims abstract description 4
- 208000010125 myocardial infarction Diseases 0.000 claims abstract description 3
- 208000029078 coronary artery disease Diseases 0.000 claims abstract 3
- 241000218176 Corydalis Species 0.000 claims description 18
- -1 amides compound Chemical class 0.000 claims description 17
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 239000011347 resin Substances 0.000 claims description 12
- 229920005989 resin Polymers 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 8
- 238000004440 column chromatography Methods 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 5
- 239000000377 silicon dioxide Substances 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 238000003810 ethyl acetate extraction Methods 0.000 claims description 3
- 239000003480 eluent Substances 0.000 claims description 2
- JXASPPWQHFOWPL-UHFFFAOYSA-N Tamarixin Natural products C1=C(O)C(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(CO)O2)O)C(=O)C2=C(O)C=C(O)C=C2O1 JXASPPWQHFOWPL-UHFFFAOYSA-N 0.000 claims 2
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 210000004165 myocardium Anatomy 0.000 claims 1
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 abstract 1
- 229950001902 dimevamide Drugs 0.000 abstract 1
- 208000006906 Vascular Ring Diseases 0.000 description 11
- 210000000709 aorta Anatomy 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 241000282472 Canis lupus familiaris Species 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 229940090044 injection Drugs 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 4
- 229930013930 alkaloid Natural products 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 210000003038 endothelium Anatomy 0.000 description 3
- 238000002481 ethanol extraction Methods 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000007157 ring contraction reaction Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940124549 vasodilator Drugs 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 241000830532 Corydalis yanhusuo Species 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000218180 Papaveraceae Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- RQBBFKINEJYDOB-UHFFFAOYSA-N acetic acid;acetonitrile Chemical compound CC#N.CC(O)=O RQBBFKINEJYDOB-UHFFFAOYSA-N 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- JUGOREOARAHOCO-UHFFFAOYSA-M acetylcholine chloride Chemical compound [Cl-].CC(=O)OCC[N+](C)(C)C JUGOREOARAHOCO-UHFFFAOYSA-M 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 230000002508 compound effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229940030825 norepinephrine injection Drugs 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000036316 preload Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Abstract
Description
树脂 | HPD100 | X-5 | DA201 | D301 | AB-8 |
得率 | 0.11% | 0.07% | 0.16% | 0.08% | 0.15 |
含量 | 80% | 65% | 56% | 58% | 76% |
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210068581.3A CN102786433B (zh) | 2012-03-15 | 2012-03-15 | 一种延胡索酰胺类化合物提取物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210068581.3A CN102786433B (zh) | 2012-03-15 | 2012-03-15 | 一种延胡索酰胺类化合物提取物及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102786433A CN102786433A (zh) | 2012-11-21 |
CN102786433B true CN102786433B (zh) | 2016-09-21 |
Family
ID=47152041
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210068581.3A Active CN102786433B (zh) | 2012-03-15 | 2012-03-15 | 一种延胡索酰胺类化合物提取物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102786433B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101062106A (zh) * | 2006-04-25 | 2007-10-31 | 长春英联生物技术有限公司 | 延胡索提取物分散片及其制备方法 |
CN101284050A (zh) * | 2008-05-09 | 2008-10-15 | 浙江康恩贝制药股份有限公司 | 延胡索水溶性部位药物及制备方法和用途 |
CN101406527A (zh) * | 2008-11-27 | 2009-04-15 | 黑龙江中医药大学 | 延胡索总生物碱盐的制备方法及其作为治疗心血管疾病药物的应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA06001225A (es) * | 2003-08-04 | 2006-04-11 | Bristol Myers Squibb Co | Metodos de tratamiento de enfermedad cardiovascular usando una molecula soluble de ctla4. |
KR100518184B1 (ko) * | 2003-12-27 | 2005-10-04 | 한국화학연구원 | 퓨란카보닐구아니딘 유도체, 그의 제조방법 및 그를포함하는 약학적 조성물 |
DE102006016817A1 (de) * | 2006-04-07 | 2007-10-11 | Henkel Kgaa | Aufhell- und/oder Färbemittel mit guter Hautverträglichkeit |
-
2012
- 2012-03-15 CN CN201210068581.3A patent/CN102786433B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101062106A (zh) * | 2006-04-25 | 2007-10-31 | 长春英联生物技术有限公司 | 延胡索提取物分散片及其制备方法 |
CN101284050A (zh) * | 2008-05-09 | 2008-10-15 | 浙江康恩贝制药股份有限公司 | 延胡索水溶性部位药物及制备方法和用途 |
CN101406527A (zh) * | 2008-11-27 | 2009-04-15 | 黑龙江中医药大学 | 延胡索总生物碱盐的制备方法及其作为治疗心血管疾病药物的应用 |
Non-Patent Citations (2)
Title |
---|
Aryl chlorothionoformate: A new versatile reagent for the preparation of Nitriles and Isonitriles under mild conditions;D.Subhas Bose,P.Ravinder Goud;《Tetrahedron Letters》;19991231;第40卷;第748页表1 * |
The synthesis of deuterium-labeled 2-bromoethanol, acrylonitrile, acrylamide, 2-aminoethanol, 2-bromoethylamine hydrobromide and 1-bromo-2-chloroethane;Ian Bird,Peter B.Farmer;《Journal of Labelled Compounds and Radiopharmaceuticals》;19891231;第XXVII卷(第2期);第203页图示2 * |
Also Published As
Publication number | Publication date |
---|---|
CN102786433A (zh) | 2012-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106946766B (zh) | 马齿苋中生物碱化合物及其提取分离方法 | |
CN104306745B (zh) | 一种天麻醒脑胶囊的检测方法 | |
CN101863871B (zh) | 蔷薇红景天总苷及其医药用途和制备方法 | |
CN105866296A (zh) | 一种建立白芍的药物制剂的指纹图谱的方法 | |
CN103207255A (zh) | 一种脑心通胶囊的含量检测方法 | |
CN102274401B (zh) | 一种治疗胃病的中药制剂及其制备方法和检测方法 | |
CN102641317B (zh) | 金鸡菊提取物及其在制备抗糖尿病药物中的应用 | |
CN103884811A (zh) | 一种生物色谱比较筛选系统及其应用 | |
CN107365285B (zh) | 环新木脂素及其制备方法和用途 | |
CN106349304B (zh) | 高纯度荨麻新苷及荨麻木脂素的制备方法 | |
CN101259124A (zh) | 蟛蜞菊内酯及其衍生物的药物用途 | |
CN103272012B (zh) | 一种附子甘草提取物及其制备方法和用途 | |
CN102293827B (zh) | 一种樟树根及含有樟树根的制剂的检测方法 | |
CN103301177B (zh) | 长柱十大功劳总生物碱的制备及其质量控制方法 | |
CN103191198A (zh) | 元胡提取物及其制备方法和用途 | |
CN104027362B (zh) | 用于治疗肺癌的牛樟芝萃取物及其制备方法 | |
CN109942481B (zh) | 马齿苋中化合物Oleraisoindole A及其提取分离方法与应用 | |
CN101766664B (zh) | 一种岗梅总皂苷提取物的检测方法 | |
CN102786433B (zh) | 一种延胡索酰胺类化合物提取物及其制备方法和应用 | |
CN103940942B (zh) | 一种肠炎宁制剂的检测方法 | |
CN104274727B (zh) | 清营口服液的质量检测方法 | |
CN105334273B (zh) | 一种地枫皮的检测方法 | |
CN103923138B (zh) | 一种烟花苷的制备方法及其应用 | |
CN109470792B (zh) | 一种同时测定党参药材中八种活性成分的hplc方法 | |
CN109771463A (zh) | 新疆一枝蒿提取物及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A fumaramide compound extract and its preparation method and application Effective date of registration: 20221024 Granted publication date: 20160921 Pledgee: Bank of China Limited Lanxi Sub-branch Pledgor: ZHEJIANG CONBA PHARMACEUTICAL Co.,Ltd. Registration number: Y2022980019363 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20160921 Pledgee: Bank of China Limited Lanxi Sub-branch Pledgor: ZHEJIANG CONBA PHARMACEUTICAL Co.,Ltd. Registration number: Y2022980019363 |